Skip to main content

Research Repository

Advanced Search

All Outputs (13)

Identifying new biomarkers of aggressive Group 3 and SHH medulloblastoma using 3D hydrogel models, single cell RNA sequencing and 3D OrbiSIMS imaging (2023)
Journal Article
Linke, F., Johnson, J. E. C., Kern, S., Bennett, C. D., Lourdusamy, A., Lea, D., …Coyle, B. (2023). Identifying new biomarkers of aggressive Group 3 and SHH medulloblastoma using 3D hydrogel models, single cell RNA sequencing and 3D OrbiSIMS imaging. Acta Neuropathologica Communications, 11(1), Article 6. https://doi.org/10.1186/s40478-022-01496-4

The most common malignant brain tumour in children, medulloblastoma (MB), is subdivided into four clinically relevant molecular subgroups, although targeted therapy options informed by understanding of different cellular features are lacking. Here, b... Read More about Identifying new biomarkers of aggressive Group 3 and SHH medulloblastoma using 3D hydrogel models, single cell RNA sequencing and 3D OrbiSIMS imaging.

Establishing an In Vitro 3D Spheroid Model to Study Medulloblastoma Drug Response and Tumor Dissemination (2022)
Journal Article
Roper, S. J., & Coyle, B. (2022). Establishing an In Vitro 3D Spheroid Model to Study Medulloblastoma Drug Response and Tumor Dissemination. Current Protocols, 2(1), Article e357. https://doi.org/10.1002/cpz1.357

Medulloblastoma is the most common malignant pediatric brain tumor. Current treatment involves surgery, chemotherapy, and craniospinal radiotherapy, and these are associated with a significant reduction in quality of life. Metastatic dissemination at... Read More about Establishing an In Vitro 3D Spheroid Model to Study Medulloblastoma Drug Response and Tumor Dissemination.

Chemosensitization of temozolomide-resistant pediatric diffuse midline glioma using potent nanoencapsulated forms of a N(3)-propargyl analogue (2021)
Journal Article
Heravi Shargh, V., Luckett, J., Bouzinab, K., Paisey, S., Turyanska, L., Singleton, W. G., …Coyle, B. (2021). Chemosensitization of temozolomide-resistant pediatric diffuse midline glioma using potent nanoencapsulated forms of a N(3)-propargyl analogue. ACS Applied Materials and Interfaces, 13(30), 35266-35280. https://doi.org/10.1021/acsami.1c04164

The lack of clinical response to the alkylating agent temozolomide (TMZ) in pediatric diffuse midline/intrinsic pontine glioma (DIPG) has been associated with O6-methylguanine-DNA-methyltransferase (MGMT) expression and mismatch repair deficiency. He... Read More about Chemosensitization of temozolomide-resistant pediatric diffuse midline glioma using potent nanoencapsulated forms of a N(3)-propargyl analogue.

3D spheroid models of paediatric SHH medulloblastoma mimic tumour biology, drug response and metastatic dissemination (2021)
Journal Article
Roper, S. J., Linke, F., Scotting, P. J., & Coyle, B. (2021). 3D spheroid models of paediatric SHH medulloblastoma mimic tumour biology, drug response and metastatic dissemination. Scientific Reports, 11(1), Article 4259. https://doi.org/10.1038/s41598-021-83809-6

© 2021, The Author(s). Studying medulloblastoma, the most common malignant paediatric brain tumour, requires simple yet realistic in vitro models. In this study, we optimised a robust, reliable, three-dimensional (3D) culture method for medulloblasto... Read More about 3D spheroid models of paediatric SHH medulloblastoma mimic tumour biology, drug response and metastatic dissemination.

ABCB1 inhibition provides a novel therapeutic target to block TWIST1-induced migration in medulloblastoma (2021)
Journal Article
Nasir, A., Cardall, A., Othman, R. T., Nicolaou, N., Lourdusamy, A., Linke, F., …Coyle, B. (2021). ABCB1 inhibition provides a novel therapeutic target to block TWIST1-induced migration in medulloblastoma. Neuro-Oncology Advances, 3(1), https://doi.org/10.1093/noajnl/vdab030

Background: Therapeutic intervention in metastatic medulloblastoma is dependent upon elucidating the underlying metastatic mechanism. We investigated whether an epithelialmesenchymal transition (EMT)-like pathway could drive medulloblastoma metastasi... Read More about ABCB1 inhibition provides a novel therapeutic target to block TWIST1-induced migration in medulloblastoma.

Y-box binding protein-1: A neglected target in pediatric brain tumors? (2020)
Journal Article
Taylor, L., Kerr, I. D., & Coyle, B. (2021). Y-box binding protein-1: A neglected target in pediatric brain tumors?. Molecular Cancer Research, 19(3), 375-387. https://doi.org/10.1158/1541-7786.MCR-20-0655

© 2020 American Association for Cancer Research. Brain and central nervous system tumors represent the most common childhood solid tumors. Comprising 21% of all pediatric cancers, they remain the leading cause of cancer-related mortality and morbidit... Read More about Y-box binding protein-1: A neglected target in pediatric brain tumors?.

3D hydrogels reveal medulloblastoma subgroup differences and identify extracellular matrix subtypes that predict patient outcome (2020)
Journal Article
Linke, F., Aldighieri, M., Lourdusamy, A., Grabowska, A. M., Stolnik, S., Kerr, I. D., …Coyle, B. (2021). 3D hydrogels reveal medulloblastoma subgroup differences and identify extracellular matrix subtypes that predict patient outcome. Journal of Pathology, 253(3), 326-338. https://doi.org/10.1002/path.5591

© 2020 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland. Medulloblastoma (MB) is the most common malignant brain tumour in children and is subdivided into... Read More about 3D hydrogels reveal medulloblastoma subgroup differences and identify extracellular matrix subtypes that predict patient outcome.

Leptomeningeal malignancy of childhood: sharing learning between childhood leukaemia and brain tumour trials (2020)
Journal Article
Walker, D. A., Meijer, L., Coyle, B., & Halsey, C. (2020). Leptomeningeal malignancy of childhood: sharing learning between childhood leukaemia and brain tumour trials. Lancet Child and Adolescent Health, 4(3), 242-250. https://doi.org/10.1016/s2352-4642%2819%2930333-5

Leptomeningeal malignancy complicates childhood cancers, including leukaemias, brain tumours, and solid tumours. In leukaemia, such malignancy is thought to invade leptomeninges via the vascular route. In brain tumours, dissemination from the primary... Read More about Leptomeningeal malignancy of childhood: sharing learning between childhood leukaemia and brain tumour trials.

A role for ABCB1 in prognosis, invasion and drug resistance in ependymoma (2019)
Journal Article
Sabnis, D. H., Storer, L. C. D., Liu, J., Jackson, H. K., Kilday, J. P., Grundy, R. G., …Coyle, B. (2019). A role for ABCB1 in prognosis, invasion and drug resistance in ependymoma. Scientific Reports, 9(1), 1-9. https://doi.org/10.1038/s41598-019-46700-z

© 2019, The Author(s). Three of the hallmarks of poor prognosis in paediatric ependymoma are drug resistance, local invasion and recurrence. We hypothesised that these hallmarks were due to the presence of a sub-population of cancer stem cells expres... Read More about A role for ABCB1 in prognosis, invasion and drug resistance in ependymoma.

A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells (2018)
Journal Article
Ahmed, E. M., Bandopadhyay, G., Coyle, B., & Grabowska, A. M. (2018). A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells. Cellular Oncology, 41(3), https://doi.org/10.1007/s13402-018-0374-8

Purpose Glioblastoma Multiforme (GBM) is the commonest brain tumour in adults. A population of cells, known as cancer stem cells (CSCs), is thought to mediate chemo/radiotherapy resistance. CD133 is a cell surface marker to identify and isolate... Read More about A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells.

Overcoming multiple drug resistance mechanisms in medulloblastoma (2014)
Journal Article
Othman, R., Coyle, B., Kimishi, I., Bradshaw, T. D., Storer, L., Korshunov, A., …Kerr, I. D. (2014). Overcoming multiple drug resistance mechanisms in medulloblastoma. Acta Neuropathologica Communications, 2(1), Article 57. https://doi.org/10.1186/2051-5960-2-57

© 2014 Othman et al.; licensee BioMed Central Ltd. Introduction: Medulloblastoma (MB) is the most common malignant paediatric brain tumour. Recurrence and progression of disease occurs in 15-20% of standard risk and 30-40% of high risk patients. We a... Read More about Overcoming multiple drug resistance mechanisms in medulloblastoma.

Histone Deacetylase Inhibition Attenuates Cell Growth with Associated Telomerase Inhibition in High-Grade Childhood Brain Tumor Cells (2010)
Journal Article
Rahman, R., Osteso-Ibanez, T., Hirst, R. A., Levesley, J., Kilday, J., Quinn, S., …Grundy, R. G. (2010). Histone Deacetylase Inhibition Attenuates Cell Growth with Associated Telomerase Inhibition in High-Grade Childhood Brain Tumor Cells. Molecular Cancer Therapeutics, 9(9), 2568-2581. https://doi.org/10.1158/1535-7163.mct-10-0272

Aberrant epigenetic regulation of gene expression contributes to tumor initiation and progression. Studies from a plethora of hematologic and solid tumors support the use of histone deacetylase inhibitors (HDACi) as potent anticancer agents. However,... Read More about Histone Deacetylase Inhibition Attenuates Cell Growth with Associated Telomerase Inhibition in High-Grade Childhood Brain Tumor Cells.

Pediatric Ependymoma: Biological Perspectives (2009)
Journal Article
Kilday, J., Rahman, R., Dyer, S., Ridley, L., Lowe, J., Coyle, B., & Grundy, R. (2009). Pediatric Ependymoma: Biological Perspectives. Molecular Cancer Research, 7(6), 765-786. https://doi.org/10.1158/1541-7786.mcr-08-0584

Pediatric ependymomas are enigmatic tumors that continue to present a clinical management challenge despite advances in neurosurgery, neuroimaging techniques, and radiation therapy. Difficulty in predicting tumor behavior from clinical and histologic... Read More about Pediatric Ependymoma: Biological Perspectives.